Fosamax® linked with osteonecrosis which destroys the jaw bone

Fosamax^®, made by Merck, has been prescribed to help reverse bone loss associated with osteoporosis. Both men and women have been prescribed Fosamax^® to prevent thinning bones. Although there are various side effects of Fosamax^® including irritation of the esophagus, chest pains, and other upper digestive problems, the latest concern is possible jaw deterioration.

Osteonecrosis of the jaw typically develops after minor dental work, and because Fosamax^® remains in the body for many months or years after treatment, even patients who are no longer using Fosamax^® are at an increased risk for ONJ. Individuals suffering from ONJ may experience severe infections with painful symptoms like facial discomfort or numbness, gum swelling, drainage, and poor gum healing. Additionally, victims of ONJ may experience tooth loss and other disfiguring side effects. Treatment of osteonecrosis of the jaw may include long-term antibiotic use, surgical reduction of damaged bone, or similar alternatives. However, ONJ is extremely resistant to most treatments and careful planning is required, as invasive surgical techniques can worsen the condition.

Fosamax^® was recently shown to have a higher incidence of ONJ than other bisphosphonates in a study conducted by the U.S. Food and Drug Administration. Additionally, evidence suggests that Merck failed to update the Fosamax^® label to reflect the danger in a timely manner, exposing millions of users to potential injury unnecessarily. Fortunately, the fosamax lawyer at the Haines Firm have the experience, knowledge, and resources to successfully represent ONJ victims against giant corporations like Merck.